SCHEMBL611762

SCHEMBL611762

Oc1ccc(Cl)c(-c2ccc3nc(Nc4ccc(OCCN5CCNCC5)cc4)nn3c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 13/20 0.53
YES1 P07947 3/20 0.53
PDGFRB P09619 3/20 0.53
ABL1 P00519 2/20 0.53
KDR P35968 2/20 0.53
EPHB4 P54760 2/20 0.53
CIT O14578 1/20 0.53
GAK O14976 1/20 0.53
EPHB6 O15197 1/20 0.53
RIPK2 O43353 1/20 0.53
PRKD3 O94806 1/20 0.53
LCK P06239 1/20 0.53
RET P07949 1/20 0.53
BCR P11274 1/20 0.53
BRAF P15056 1/20 0.53
EPHA2 P29317 1/20 0.53
EPHB2 P29323 1/20 0.53
TYK2 P29597 1/20 0.53
ACVR1B P36896 1/20 0.53
TGFBR1 P36897 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL612970 0.93 SRC (0.62) SRCYES1PDGFRBABL1KDR
SCHEMBL615134 0.90 SRC (0.53) SRCYES1PDGFRBABL1KDR
SCHEMBL612376 0.86 SRC (0.46) SRCYES1PDGFRBABL1KDR
SCHEMBL614557 0.84 SRC (0.63) SRCYES1PDGFRBABL1KDR
SCHEMBL42350 0.83 SRC (0.51) SRCYES1PDGFRBABL1KDR
SCHEMBL613798 0.82 ESR1 (0.45) SRCYES1PDGFRBABL1KDR
SCHEMBL40821 0.82 SRC (0.49) SRCYES1PDGFRBABL1KDR
SCHEMBL40869 0.82 SRC (0.52) SRCYES1PDGFRBABL1KDR
SCHEMBL612666 0.82 SRC (0.55) SRCYES1PDGFRBABL1KDR
SCHEMBL615141 0.81 SRC (0.62) SRCYES1PDGFRBABL1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041195-A1 Heterocyclic compounds FOVEA PHARMACEUTICALS 2012-02-16 US claimed
EP-2396324-A1 Ý1, 2, 4¨TRIAZOLO Ý1, 5 -A¨PYRIDINES AS KINASE INHIBITORS Fovea Pharmaceuticals (FR) 2011-12-21 EP claimed
WO-2010092041-A1 [1, 2, 4] TRIAZOLO [1, 5 -A] PYRIDINES AS KINASE INHIBITORS FOVEA PHARMACEUTICALS SA (FR) 2010-08-19 WO claimed
US-20120041195-A1 Heterocyclic compounds FOVEA PHARMACEUTICALS 2012-02-16 US disclosed
EP-2396324-A1 Ý1, 2, 4¨TRIAZOLO Ý1, 5 -A¨PYRIDINES AS KINASE INHIBITORS Fovea Pharmaceuticals (FR) 2011-12-21 EP disclosed
WO-2010092041-A1 [1, 2, 4] TRIAZOLO [1, 5 -A] PYRIDINES AS KINASE INHIBITORS FOVEA PHARMACEUTICALS SA (FR) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041195-A1 Heterocyclic compounds MAP3K1, MAP3K5, MAP3K2 SRC 1204/4885YES1 779/4885PDGFRB 941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.